From 732b36b341f4b3fd1c85103866ddaafe12fdc9a7 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 8 May 2026 21:44:42 +0000 Subject: [PATCH] vida: extract claims from 2026-03-05-omada-health-fy2025-results-first-profitable-quarter - Source: inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...superior-unit-economics-versus-coaching-only-models.md | 8 +++++++- ...0-percentage-points-through-coaching-and-monitoring.md | 7 +++++++ ...ng-behavioral-support-without-drug-benefit-exposure.md | 7 +++++++ ...mada-health-fy2025-results-first-profitable-quarter.md | 5 ++++- 4 files changed, 25 insertions(+), 2 deletions(-) rename inbox/{queue => archive/health}/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md (98%) diff --git a/domains/health/cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models.md b/domains/health/cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models.md index 8dcf58914..454b0033a 100644 --- a/domains/health/cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models.md +++ b/domains/health/cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models.md @@ -34,4 +34,10 @@ Omada Health achieved profitability ($5.16M net income) at $260M annual revenue **Source:** WW Clinic 2026 program structure, Hit Consultant December 2025 -WeightWatchers' diabetes program with FreeStyle Libre CGM shows strong clinical outcomes (0.9 HbA1c reduction at 6 months, 33.8% depression reduction, 62% physical function increase), but WW chose NOT to extend CGM to its general GLP-1 Med+ program despite having the Abbott partnership. This selective deployment—diabetes yes, obesity no—suggests either (a) CGM reimbursement constraints limit economic viability outside diabetes indication, or (b) organizational recognition that the physical integration moat works for diabetes but faces different economics in obesity market. \ No newline at end of file +WeightWatchers' diabetes program with FreeStyle Libre CGM shows strong clinical outcomes (0.9 HbA1c reduction at 6 months, 33.8% depression reduction, 62% physical function increase), but WW chose NOT to extend CGM to its general GLP-1 Med+ program despite having the Abbott partnership. This selective deployment—diabetes yes, obesity no—suggests either (a) CGM reimbursement constraints limit economic viability outside diabetes indication, or (b) organizational recognition that the physical integration moat works for diabetes but faces different economics in obesity market. + +## Challenging Evidence + +**Source:** Omada Health FY2025 earnings report, March 5, 2026; agent notes confirm CGM absence for obesity program + +Omada achieved profitability and 66% gross margins in FY2025 WITHOUT CGM integration for general obesity/GLP-1 programs (CGM only used in diabetes program). This challenges the claim that CGM integration is necessary for superior unit economics, as behavioral coaching + AI oversight alone achieved positive economics. diff --git a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md index e6021e9b0..b54be20be 100644 --- a/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md +++ b/domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md @@ -85,3 +85,10 @@ Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks **Source:** Omada Health clinical outcomes data, March 2026 Omada members who persisted on GLP-1 for 12 months achieved 18.4% average weight loss and 44% greater weight loss on semaglutide versus real-world evidence, suggesting behavioral support improves not just persistence but also on-medication efficacy. + + +## Supporting Evidence + +**Source:** Omada Health FY2025 earnings report, March 5, 2026 + +Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort, representing an 18-20 percentage point improvement. Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3%, which is 44% better than real-world semaglutide evidence. diff --git a/domains/health/employer-glp1-cash-pay-model-separates-program-cost-from-medication-cost-enabling-behavioral-support-without-drug-benefit-exposure.md b/domains/health/employer-glp1-cash-pay-model-separates-program-cost-from-medication-cost-enabling-behavioral-support-without-drug-benefit-exposure.md index fdb8b8f36..53932bc39 100644 --- a/domains/health/employer-glp1-cash-pay-model-separates-program-cost-from-medication-cost-enabling-behavioral-support-without-drug-benefit-exposure.md +++ b/domains/health/employer-glp1-cash-pay-model-separates-program-cost-from-medication-cost-enabling-behavioral-support-without-drug-benefit-exposure.md @@ -24,3 +24,10 @@ Omada Health's GLP-1 Flex Care represents a structural financial innovation in r **Source:** Omada Health GLP-1 Flex Care announcement, March 2026 Omada's GLP-1 Flex Care is the first concrete employer product implementing this model at scale. Designed for the 55% of employers who don't cover GLP-1 medications, it allows employers to pay for behavioral support (coaching, nutrition, clinical oversight) while members purchase medications independently through cash-pay channels. This validates the theoretical model with an actual market offering launching H2 2026. + + +## Supporting Evidence + +**Source:** Omada Health FY2025 earnings report, March 5, 2026 + +Omada launched GLP-1 Flex Care on March 5, 2026: employer pays for behavioral support program while member uses existing pharmacy benefits for medication. This directly addresses employer concern about medication cost exposure while maintaining access to behavioral support infrastructure. diff --git a/inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md b/inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md similarity index 98% rename from inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md rename to inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md index 80176d05c..1a4c0d982 100644 --- a/inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md +++ b/inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md @@ -7,10 +7,13 @@ date: 2026-03-05 domain: health secondary_domains: [] format: earnings-report -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-08 priority: high tags: [Omada, digital-health, GLP-1, behavioral-health, atoms-to-bits, VBC, employer-market, IPO] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content